A cure that markets itself.And the clinical infrastructure to deliver it.
An application-only acne research cohort for serious practitioners. Two patient channels — your own clients and BMH-assigned referrals. Prescription-anchored topical protocol, gut-microbiome pathway for systemic cases, and a clinical operating system that resolves what most practices only manage.
Acne is the most under-served, highest-referral presentation in your practice.
Most practitioners — even excellent ones — do not have a credible answer for acne. Conventional dermatology trades efficacy for barrier damage. Functional approaches trade clarity for endless supplement stacks. Patients ask anyway. They are asking right now.
A cleared patient is the only marketing this program needs.
Acne resolution is visible in a way no other clinical outcome is. A cleared patient tells three to five people in their immediate circle with the same struggle — and those people can see the result on their face. Referral compounding alone fills the next cohort.
Cleared patients become your highest-LTV clients.
A patient whose face you fixed will let you run their hormones, their gut, their longevity panels, their peptides. The conversion rate from cleared acne to one additional service line is meaningfully higher than for any transactional patient relationship in functional medicine.
Resolution, not management.
Treated correctly at the gut microbiome, acne does not recur. This is not a maintenance subscription dressed up as a program. It is a definitive intervention with publishable outcomes — and a research cohort designed to prove it.
You have been told acne is chronic.
It is not.
A turnkey acne offering, deployable from day one.
A 12-week, two-pathway protocol anchored in prescription-grade stabilized hypochlorous acid (EO-100), supported by a choreographed sequence of clinical-grade topical activators, with a gut-microbiome repair pathway for systemic cases.
For cutaneous-driven cases.
Full topical clarity system: EO-100 prescription anchor, plus the Rə'jōōv / Rə'act / Rə'stôr activator sequence. Bi-weekly automated tracking. Acceptance interview and completion consultation handled by the BMH clinical team.
For systemic involvement.
Everything in Protocol 01, layered over the Seed · Net · Clear gut-microbiome repair sequence. Liposomal glutathione, binders, mitophagy support. Phase-transition coordination throughout the 12 weeks.
EO-100 prescription is issued under a Program Prescriber on the BMH supervising team — or, where the referring practitioner holds prescribing authority, under their own license. Either path delivers the same protocol.
Patients you bring. Patients we send.
Both channels feed the same 200-patient research cohort. Both produce the same revenue layers for your practice. The difference is where the patient came from — and which channel is open to you depends on the tier you enter at.
Your own clients.
Bring patients from your existing practice into the cohort — they stay your client throughout. If you provide the products, you can earn margin on the topical kit and the supplementation line, and there are a few ways to structure it. You don't have to: you can simply refer them and they go through the program as a regular BMH client. Either way, the protocol clears them, and they refer their friends — to you.
BMH-assigned patients.
Patients who apply through our patient-facing acne clarity page are routed to membership-tier practitioners on the directory. Patient flow into your practice — without acquisition spend, geographically matched, clinically pre-qualified.
Three layers of revenue. One compounding engine.
Acne treated correctly does not generate recurring product revenue — patients clear and stay clear. The compelling math sits elsewhere: in the patients those cleared patients send you, and in the lifetime value of relationships built on a visible win.
Acquisition margin.
50% wholesale margin on the topical kit. 30% margin on Protocol 02 supplementation through Fullscript. Per-patient economics are reviewed during the application interview, where bundled program pricing is unwound transparently.
Referral compounding.
A cleared acne patient refers three to five people in their immediate circle. At a 20–25% conversion rate, ten cleared patients seeds another six to ten enrollments over the following six to twelve months — and that cohort seeds the next. By month 18, the acne program is the lowest-cost source of new patients in your practice — they arrive by referral, not paid marketing.
Patient lifetime value.
Cleared patients convert to other service lines at materially higher rates than transactional patients. Conservative assumption: 50% of retained cohort patients convert to one additional service at $1,500–2,500 per year. The acne program becomes the front door to the rest of your practice.
Cohort participation, at the depth your practice requires.
Every level includes the monthly cohort meeting with Dr. Lily Woods, PhD. Membership tiers add the Six Pathway clinical infrastructure that extends the methodology across every other condition you treat. Founding-cohort pricing is locked through 2027.
Practitioner
Cohort Practitioner is a free, application-only entry tier. It exists to let serious practitioners experience the methodology and the cohort meeting before committing to membership. Soft-capped at three active patients to keep the tier honest about what it is — and what it is not.
Two decades of precision longevity, applied to acne.
Dr. Lily Woods, PhD is the protocol designer behind Body MAX Harmonics. Her work sits at the intersection of precision longevity, regenerative health, and advanced diagnostic testing — with depth in the gut-microbiome biology that drives systemic acne presentations.
The acne research cohort is the first published outcomes study from the BMH platform. It exists to prove what the methodology can do when applied to a single, visible, high-impact presentation — and to bring that proof to the practitioners running it in their own practices.
Dr. Woods runs the monthly cohort meeting personally. Every cohort patient case is reviewable. Every protocol decision is teachable. Every cleared patient is data.
Who this cohort is built for.
Are you a licensed prescriber?
If you hold prescribing authority and are interested in serving as a prescribing clinician inside the cohort itself — issuing EO-100 prescriptions for cohort patients matched to your state licensure — apply through the Program Prescriber pathway. Compensation is structured into the program. Geographic match is handled at intake. The role is separate from practitioner tier participation, and a single prescriber may hold both.
What approved practitioners ask before applying.
The cohort is a structured research program, not open enrollment. Capping it at 200 patient seats keeps the data clean, gives every participant real clinical oversight, and protects founding-cohort terms for the practitioners selected. When the seats fill, the founding window closes.
Patients who apply through the patient-facing acne clarity page are matched by geography and licensure to membership-tier practitioners on the BMH directory, then routed into your practice. The patient is clinically pre-qualified before they reach you, and there is no acquisition spend on your side. This channel opens at the membership tiers.
Cohort Practitioner is the entry level: you join the research cohort, attend the monthly cohort meeting with Dr. Woods, and can bring your own clients through the protocol (Channel 01). It does not include the Six Pathway BOT infrastructure or BMH-assigned patient routing — those open at the Essential, Foundation, and Apex membership tiers.
Apex members can participate in the cohort's research and be named as contributing authors on resulting publications. The specific authorship criteria are set out in, and agreed to as part of, the application — so the terms are clear and mutual before acceptance. It is a genuine research role, not an honorary credit.
EO-100 is issued under a licensed Program Prescriber on the BMH supervising team matched to the patient's state, or under your own license where you hold prescribing authority. Geographic match is confirmed at intake as the prescriber network is aligned to state licensure.
The founding window closes when the cohort's practitioner and patient seats are filled. Practitioners accepted during this window keep founding-cohort pricing, locked through 2027.
Each patient closes with an outcomes review. Acne treated correctly clears and stays clear, so there is no manufactured recurring product dependency. The value continues through the relationship: cleared patients stay in your practice for other care and refer the people around them.
This is not a purchase. It is an admission.
Enrollment in the founding cohort is limited and reviewed on a rolling basis. Every applicant is read by Dr. Woods personally. Where there is alignment, the next step is a conversation. Where there is not, we will tell you so directly.
Per-patient economics · Comprehensive (Protocol 02)
The trial is the entry point.
The patient is the annuity.
The Comprehensive gut-microbiome trial earns margin once, during the 12 weeks. Then the patient stays with you — refilling supplements through your dispensary and reordering topicals — for as long as you keep them. Protocol 02 is open to Essential members and above. Set your own numbers to see what it is worth.
Your inputs
Determines how much of the $2,495 patient fee stays with your practice instead of going to BMH.
What you spend at cost on the supplements and kits you supply. Leave at 0 to see gross.
Ongoing dispensary and topical reorder margin once the trial ends.
Per patient
Total value per patient (trial + retention)
$1,960
One referred patient, kept for 12 months.
At your volume
Your membership also earns beyond acne — across every client you run through the BMH system.
This is a member benefit
The Comprehensive (Protocol 02) trial is open to Essential, Clinical, and APEX members. The free Cohort Practitioner tier covers Protocol 01 topical only.
Illustrative only and not a guarantee of income. Figures depend on your actual product costs, the margin you set in your own dispensary, patient adherence, and how long patients stay. “Recurring at steady state” is the monthly recurring margin once your retained base has built up over roughly the retention period you entered; it accrues gradually rather than from day one. This tool is for planning and does not constitute financial advice.
Everything included
Everything your client receives.
Protocol 02 · Full gut-microbiome pathway · 12 weeks
Total value if assembled separately
$4,145
Your client's price: $2,495
More than $1,650 in added value
Resolution, not management — and an outcome that contributes to published research.
The topical kit
The topical clarity kit.
The Angry Acne activator sequence plus an Eminence Organic Skin Care cleanser — used across Protocol 01 and Protocol 02.
Each product is used on the schedule set in the protocol.
The membership ROI math
Your membership earns across your whole practice.
Membership runs the BMH clinical system — Bot 1 disease-state protocols, Bot 2 individualized patient protocols, and the Six Pathway framework — for every client you treat. It pays for itself on practice economics alone:
Membership levels
One repriced protocol covers the month.
A single premium protocol package ($300–$1,500) can cover a full month of membership outright. Across a working caseload — every protocol, every supplementation cycle, every retest visit — the membership returns many times its monthly cost.
Figures reflect typical BMH practice economics and vary by practice, tier, and case mix.